Table II.
Association between CLEC4M expression and certain clinicopathological features.
| Association with CLEC4M expression | ||||
|---|---|---|---|---|
| Clinicopathological feature | Patients, n (%) | Negative and weak (%) | Moderate and strong (%) | P-value |
| Sex | 0.984 | |||
| Female | 6 (6.82) | 4 (66.7) | 2 (33.3) | |
| Male | 82 (93.18) | 55 (67.07) | 27 (32.93) | |
| Age, years | 0.788 | |||
| ≤50 | 29 (32.95) | 20 (68.97) | 9 (31.03) | |
| >50 | 59 (67.05) | 39 (66.10) | 20 (33.90) | |
| HBsAg | 0.668 | |||
| Negative | 11 (14.29) | 8 (72.72) | 3 (27.28) | |
| Positive | 77 (85.71) | 51 (66.23) | 26 (33.77) | |
| AFP, ng/ml | 0.408 | |||
| ≤20 | 40 (45.45) | 25 (62.50) | 15 (37.50) | |
| >20 | 48 (54.55) | 34 (70.83) | 14 (29.17) | |
| Liver cirrhosis | 0.466 | |||
| No | 32 (36.36) | 23 (78.88) | 9 (21.12) | |
| Yes | 56 (63.64) | 36 (64.29) | 20 (35.71) | |
| Tumor number | 0.412 | |||
| Single | 75 (85.23) | 49 (62.82) | 26 (37.18) | |
| Multiple | 13 (14.77) | 10 (76.92) | 3 (23.08) | |
| Tumor size, cm | 0.018a | |||
| ≤5 | 52 (59.09) | 40 (81.13) | 12 (18.87) | |
| >5 | 36 (40.91) | 19 (52.78) | 17 (47.22) | |
| Tumor encapsulation | <0.001c | |||
| Complete | 58 (65.91) | 47 (81.03) | 11 (18.97) | |
| None | 30 (34.09) | 12 (40.00) | 18 (60.00) | |
| Microvascular invasion | 0.008b | |||
| Absence | 42 (47.73) | 34 (80.95) | 8 (19.05) | |
| Present | 46 (52.27) | 25 (54.35) | 21 (45.65) | |
| TNM stage | 0.019a | |||
| I+II | 46 (52.27) | 36 (78.26) | 10 (21.74) | |
| III+IV | 42 (47.73) | 23 (54.76) | 19 (45.24) | |
| BCLC stage | 0.548 | |||
| 0+A | 70 (79.54) | 48 (68.57) | 22 (31.43) | |
| B+C | 18 (20.46) | 11 (61.11) | 7 (38.89) | |
| HBV-DNA | 0.703 | |||
| Negative | 42 (47.73) | 29 (69.05) | 13 (30.95) | |
| Positive | 46 (52.27) | 30 (65.22) | 16 (34.78) | |
HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; BCLC stage, Barcelona clinic liver cancer stage; HBV, hepatitis B virus; CLEC4M, C-type lectin domain family 4 member M.
a
P<0.05
b
P<0.01
c
P<0.001.